Biacore Awarded Damages in Patent Dispute

Estimated Amount: USD 1.7 million



Apr 27, 2001, 01:00 ET from Biacore International AB

    UPPSALA, Sweden, April 27 /PRNewswire/ --
 Biacore International AB (Biacore) (Nasdaq:   BCOR) (SSE: BCOR) today announced
 that, on April 23, 2001, the U.S. District Court for the District of Delaware
 granted a permanent injunction preventing Thermo Bioanalysis Corp (Thermo)
 from infringing Biacore's patent (U.S. patent no. 5,436,161).  Furthermore,
 the Court awarded damages in favor of Biacore AB and Biacore Inc. to be
 calculated based upon a royalty rate of 40% of the sales price of each IAsys
 biosensor sold by Thermo since July 25, 1995, plus interest.
     Although the final amount due to Biacore has not been determined at this
 time, it is estimated to be in the region of USD 1.7 million.
     The decision of the Court can be appealed to the Court of Appeals for the
 Federal Circuit, the centralized appellate Court for patent appeals in the
 United States.
 
     Background
     On December 30, 1999, the U.S. District Court for the District of Delaware
 announced its decision in the patent dispute between Biacore and Thermo.  The
 Court decided in Biacore's favor, holding that Biacore's patent was valid and
 that the patent had been infringed by Thermo's Affinity Sensors unit.  The
 Court further indicated that it "would grant a permanent injunction preventing
 Thermo from infringing the '161 patent' and requested further briefing
 regarding the amount of damages to be paid by Thermo for its past infringement
 and concerning the language of the permanent injunction.  The Court's
 April 23, 2001 Judgment addressed these outstanding issues.
 
     This press release contains certain forward-looking statements within the
 meaning of the United States Private Securities Litigation Reform Act of 1995,
 which, by their nature, involve risk and uncertainty because they relate to
 events and depend on circumstances that will occur in the future.  There are a
 number of factors that could cause actual results and developments to differ
 materially from those expressed or implied by these forward-looking
 statements.
 
     Notes to editors:
     Biacore is a global market leader in Surface Plasmon Resonance (SPR) based
 technology with its own sales operations in the U.S., across Europe, in Japan,
 Australia and New Zealand.  The technology is protected by a strong patent
 portfolio.  Target groups consist primarily of medical and life science
 research laboratories and pharmaceutical and biotechnology companies all over
 the world.  Biacore focuses on drug discovery as the prime area for future
 growth.  The company currently has six systems on the market with its
 BIACORE(R)3000 system offering specific application in drug discovery
 processes upstream of high-throughput screening (HTS).  A new high-performance
 system is currently under late-stage development and will focus on
 applications downstream of HTS.
 
     Based in Uppsala, Sweden, the company is listed on the Stockholm Stock
 Exchange and Nasdaq in the U.S.  In 2000 the company has sales of
 SEK 438.8 million and an operating income of SEK 78.0 million.
 
     Further information on Biacore can be found on the web: www.biacore.com .
 
     Address and phone:  Biacore International AB
                         Rapsgatan 7, SE-754 50 Uppsala, SWEDEN
                         Phone: +46 (0)18-675700 Fax: +46 (0)18-150111
                         info@biacore.com
 
 

SOURCE Biacore International AB
    UPPSALA, Sweden, April 27 /PRNewswire/ --
 Biacore International AB (Biacore) (Nasdaq:   BCOR) (SSE: BCOR) today announced
 that, on April 23, 2001, the U.S. District Court for the District of Delaware
 granted a permanent injunction preventing Thermo Bioanalysis Corp (Thermo)
 from infringing Biacore's patent (U.S. patent no. 5,436,161).  Furthermore,
 the Court awarded damages in favor of Biacore AB and Biacore Inc. to be
 calculated based upon a royalty rate of 40% of the sales price of each IAsys
 biosensor sold by Thermo since July 25, 1995, plus interest.
     Although the final amount due to Biacore has not been determined at this
 time, it is estimated to be in the region of USD 1.7 million.
     The decision of the Court can be appealed to the Court of Appeals for the
 Federal Circuit, the centralized appellate Court for patent appeals in the
 United States.
 
     Background
     On December 30, 1999, the U.S. District Court for the District of Delaware
 announced its decision in the patent dispute between Biacore and Thermo.  The
 Court decided in Biacore's favor, holding that Biacore's patent was valid and
 that the patent had been infringed by Thermo's Affinity Sensors unit.  The
 Court further indicated that it "would grant a permanent injunction preventing
 Thermo from infringing the '161 patent' and requested further briefing
 regarding the amount of damages to be paid by Thermo for its past infringement
 and concerning the language of the permanent injunction.  The Court's
 April 23, 2001 Judgment addressed these outstanding issues.
 
     This press release contains certain forward-looking statements within the
 meaning of the United States Private Securities Litigation Reform Act of 1995,
 which, by their nature, involve risk and uncertainty because they relate to
 events and depend on circumstances that will occur in the future.  There are a
 number of factors that could cause actual results and developments to differ
 materially from those expressed or implied by these forward-looking
 statements.
 
     Notes to editors:
     Biacore is a global market leader in Surface Plasmon Resonance (SPR) based
 technology with its own sales operations in the U.S., across Europe, in Japan,
 Australia and New Zealand.  The technology is protected by a strong patent
 portfolio.  Target groups consist primarily of medical and life science
 research laboratories and pharmaceutical and biotechnology companies all over
 the world.  Biacore focuses on drug discovery as the prime area for future
 growth.  The company currently has six systems on the market with its
 BIACORE(R)3000 system offering specific application in drug discovery
 processes upstream of high-throughput screening (HTS).  A new high-performance
 system is currently under late-stage development and will focus on
 applications downstream of HTS.
 
     Based in Uppsala, Sweden, the company is listed on the Stockholm Stock
 Exchange and Nasdaq in the U.S.  In 2000 the company has sales of
 SEK 438.8 million and an operating income of SEK 78.0 million.
 
     Further information on Biacore can be found on the web: www.biacore.com .
 
     Address and phone:  Biacore International AB
                         Rapsgatan 7, SE-754 50 Uppsala, SWEDEN
                         Phone: +46 (0)18-675700 Fax: +46 (0)18-150111
                         info@biacore.com
 
 SOURCE  Biacore International AB